PubMed

Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans.

Ahrén B, Holst JJ, Mari A.

Diabetes Care. 2003 Oct;26(10):2860-4.PMID: 14514592 [PubMed - indexed for MEDLINE]Related articlesFree article

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.

Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.

Diabetes Care. 2003 Mar;26(3):791-8.PMID: 12610039 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.

Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.

Diabetes Care. 2000 Jun;23(6):807-12.PMID: 10841001 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.

Pørksen N, Grøfte B, Nyholm B, Holst JJ, Pincus SM, Veldhuis JD, Schmitz O, Butler PC.

Diabetes. 1998 Jan;47(1):45-9.PMID: 9421373 [PubMed - indexed for MEDLINE]Related articles

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

Kjems LL, Holst JJ, Vølund A, Madsbad S.

Diabetes. 2003 Feb;52(2):380-6.PMID: 12540611 [PubMed - indexed for MEDLINE]Related articlesFree article

Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes.

Gutniak MK, Svartberg J, Hellström PM, Holst JJ, Adner N, Ahrén B.

J Intern Med. 2001 Jul;250(1):81-7.PMID: 11454146 [PubMed - indexed for MEDLINE]Related articles

GLP-1-induced alterations in the glucose-stimulated insulin secretory dose-response curve.

Brandt A, Katschinski M, Arnold R, Polonsky KS, Göke B, Byrne MM.

Am J Physiol Endocrinol Metab. 2001 Aug;281(2):E242-7.PMID: 11440899 [PubMed - indexed for MEDLINE]Related articlesFree article

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.

Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.

Diabetes. 1996 Nov;45(11):1524-30.PMID: 8866556 [PubMed - indexed for MEDLINE]Related articles

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen MB, Madsbad S, Holst JJ.

Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.

Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, Schmiegel WH.

Am J Physiol. 1997 Nov;273(5 Pt 1):E981-8.PMID: 9374685 [PubMed - indexed for MEDLINE]Related articlesFree article

Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.

Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.

Exp Clin Endocrinol Diabetes. 1998;106(2):103-7.PMID: 9628239 [PubMed - indexed for MEDLINE]Related articles

Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.

Gutniak MK, Linde B, Holst JJ, Efendić S.

Diabetes Care. 1994 Sep;17(9):1039-44.PMID: 7988303 [PubMed - indexed for MEDLINE]Related articles

Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D.

Diabetes Care. 2003 Oct;26(10):2835-41.PMID: 14514588 [PubMed - indexed for MEDLINE]Related articlesFree article

Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

Meier JJ, Kemmeries G, Holst JJ, Nauck MA.

Diabetes. 2005 Jul;54(7):2212-8.PMID: 15983224 [PubMed - indexed for MEDLINE]Related articlesFree article

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T.

Diabetes Care. 2003 Sep;26(9):2581-7.PMID: 12941722 [PubMed - indexed for MEDLINE]Related articlesFree article

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.

Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA.

J Clin Endocrinol Metab. 2003 Jun;88(6):2719-25.PMID: 12788879 [PubMed - indexed for MEDLINE]Related articlesFree article

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

Rachman J, Barrow BA, Levy JC, Turner RC.

Diabetologia. 1997 Feb;40(2):205-11.PMID: 9049482 [PubMed - indexed for MEDLINE]Related articles

Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.

Schou JH, Pilgaard K, Vilsbøll T, Jensen CB, Deacon CF, Holst JJ, Vølund A, Madsbad S, Vaag AA.

J Clin Endocrinol Metab. 2005 Aug;90(8):4912-9. Epub 2005 May 17.PMID: 15899957 [PubMed - indexed for MEDLINE]Related articlesFree article